author-photo

Epie Boven

VU University Amsterdam
VU University Medical Center

245

Papers

8056

Citations

Citation Trend

Filter By

Papers (172) Sort By

Journal Conference Others

29P Plasma ESR1 mutations and outcome to first-line chemotherapy with bevacizumab and paclitaxel in patients with advanced ER-positive/HER2-negative breast cancer

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
685P Genome-wide association meta-analysis identifies novel variants that correlate with efficacy outcomes in sunitinib-treated patients with metastatic renal cell carcinoma

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Hierarchical clustering of PI3K and MAPK pathway proteins in breast cancer intrinsic subtypes

2020 Apmis
Show All
- Source
- Cite
- Save
Citations (2)
21PCharacteristics of circulating tumor DNA (ctDNA) in patients with ER-positive (ER+), HER2-negative (HER2-) metastatic breast cancer (MBC) on different lines of endocrine treatment

2019 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
150O_PRPertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression in patients with HER2-positive metastatic breast cancer (MBC) - The PERNETTA trial (SAKK 22/10), a randomized open label phase II study (SAKK, UNICANCER, BOOG)

2019 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Abstract P4-08-06: Phosphorylation of insulin-like growth factor-1 receptor (IGF-1R) is associated with tamoxifen resistance by activating the PI3K/MAPK pathway

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Hierarchical clustering of activated proteins in the PI3K and MAPK pathways in ER-positive, HER2-negative breast cancer with potential therapeutic consequences

2018 British Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (11)
288PDPERNETTA: A non-comparative randomized open label phase II trial of pertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast cancer (MBC): (SAKK 22/10 / UNICANCER UC-0140/1207)

2018 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (5)
Abstract PD4-12: Clustering of activated proteins of the PI3K and MAPK pathways distinguishes ER+/HER2- primary breast cancer patients with preferential tamoxifen benefit

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Meta-analysis on the association of VEGFR1 genetic variants with sunitinib outcome in metastatic renal cell carcinoma patients

2017 Oncotarget
Show All
- Source
- Cite
- Save
Citations (5)